Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 plus nivolumab versus placebo plus nivolumab in unresectable or metastatic melanoma
jRCT2061220112Phase 3Active, not recruiting
- Sponsor
- HUYABIO International, LLC
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing HBI-8000 + nivolumab with Placebo + nivolumab (2 arms). Primary endpoint: Progression-free Survival. Started May 2023; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2061220112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220112.